Price Alert: Shares of BioAtla (BCAB) Trade 6.51% Higher at Midday June 21

Equities Staff  |

BioAtla Inc (NASDAQ: BCAB) shares climbed 6.51%, or $0.17 per share, as on 11:44:23 est today. After Opening the Day at $2.69, 93,333 shares of BioAtla have traded hands and the stock has traded between $2.95 and $2.65.  

Already the company is down 86.70%.

BioAtla is set to release earnings on 2022-08-09.

For technical charts, analysis, and more on BioAtla visit the company profile.

About BioAtla Inc

BioAtla® is a San Diego biotech company that develops novel monoclonal antibody and cell based therapeutics using our proprietary Conditionally Active Biologics™ (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!™) platforms. These and other proprietary technologies (protected by more than 150 issued patents and patent applications) allow it to develop novel biologics (CABs) that are better drugs in multiple ways including more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment (TME), even when the target is also found in normal tissue, not only improves safety and thus therapeutic index but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers.

To get more information on BioAtla Inc and to follow the company's latest updates, you can visit the company's profile page here: BioAtla Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:

Trending Articles

The Best Laid Plans of Mice and Men — Part II
Why I’m Buying the 'New' Value Stocks
Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade

Market Movers

Sponsored Financial Content